Celecoxib is a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older Ankylosing Spondylitis (AS) Acute Pain (AP) Primary Dysmenorrhea (PD) Celecoxib capsules are indicated 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA. 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA. 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older. 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS. 1.
| Jun 9, 2015 | Original application | Approved | None posted |
| Oct 29, 2014 | Original application | Approved |
| Oct 21, 2025 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jan 5, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 9, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 9, 2019 | Supplement 7Manufacturing | Approved | None posted |
| Oct 9, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 16, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 9, 2015 | Original application | Approved | None posted |
| Oct 29, 2014 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters